Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Oct
27
Today In Oncology
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors
Impact of Digital Breast Tomosynthesis on Invasive Interval Breast Cancer Rate
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo